Cho Tae-Joon, Seo Joong-Bae, Lee Hye Ran, Yoo Won Joon, Chung Chin Youb, Choi In Ho
Department of Orthopaedic Surgery, Seoul National University Children's Hospital, 28 Yeongeon-dong Jongno-gu, Seoul 110-744, South Korea.
J Bone Joint Surg Am. 2008 Dec;90(12):2735-44. doi: 10.2106/JBJS.H.00014.
Fibrous hamartoma is a key pathologic component of congenital pseudarthrosis of the tibia, a challenging and disabling bone disorder. We investigated the biologic characteristics of fibrous hamartoma cells in order to better understand the pathogenesis of this rare disease.
Fibrous hamartoma tissues were surgically excised at the time of osteosynthesis from seven patients with congenital pseudarthrosis of the tibia associated with neurofibromatosis type 1. Distal tibial periosteum was also harvested as control tissue during tibial derotation osteotomy from two other patients with cerebral palsy and one patient with idiopathic internal tibial torsion. Fibroblast-like cells were enzymatically dissociated and cultured from these tissues. Immunophenotypes were investigated for positive (CD44 and CD105) and negative (CD45 and CD14) mesenchymal lineage cell markers, and the mRNA expressions of bone morphogenetic protein(BMP)-2, BMP-4, and their receptors were assayed by reverse transcription-polymerase chain reaction. After rhBMP-2 treatment, the changes in alkaline phosphatase activity, and in the mRNA expressions of type-I collagen (COL1A1), alkaline phosphatase, and osteocalcin genes, were assayed with use of an RNase protection assay. The mRNA expressions of receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG) were quantitatively assayed with use of real-time RT-PCR. Osteoclastic differentiation of RAW(264.7) cells in coculture with fibrous hamartoma cells was evaluated.
All fibrous hamartoma and tibial periosteal cells tested were CD44+/CD105+/CD45-/CD14- and expressed the mRNAs of BMP-2, BMP-4, and their receptors. The baseline mRNA expressions of COL1A1, alkaline phosphatase, and osteocalcin genes in the fibrous hamartoma cells were diverse. These gene expressions were upregulated by BMP treatment in tibial periosteal cells but did not change or were downregulated in fibrous hamartoma cells. Fibrous hamartoma cells expressed higher levels of RANKL and lower levels of OPG than did tibial periosteal cells. Coculture with fibrous hamartoma cells enhanced osteoclastic differentiation of RAW(264.7) cells.
Fibrous hamartoma cells maintain some of the mesenchymal lineage cell phenotypes, but do not undergo osteoblastic differentiation in response to BMP. They are more osteoclastogenic than are tibial periosteal cells.
纤维性错构瘤是胫骨先天性假关节的关键病理组成部分,胫骨先天性假关节是一种具有挑战性且使人致残的骨疾病。我们研究了纤维性错构瘤细胞的生物学特性,以便更好地理解这种罕见疾病的发病机制。
在骨合成时,从7例患有与1型神经纤维瘤病相关的胫骨先天性假关节的患者身上手术切除纤维性错构瘤组织。在另外2例脑瘫患者和1例特发性胫骨内扭转患者的胫骨旋转截骨术中,还采集了胫骨远端骨膜作为对照组织。从这些组织中酶解分离并培养成纤维细胞样细胞。研究免疫表型以检测间充质谱系细胞阳性(CD44和CD105)和阴性(CD45和CD14)标志物,并通过逆转录-聚合酶链反应检测骨形态发生蛋白(BMP)-2、BMP-4及其受体的mRNA表达。用重组人骨形态发生蛋白-2(rhBMP-2)处理后,使用核糖核酸酶保护试验检测碱性磷酸酶活性以及I型胶原(COL1A1)、碱性磷酸酶和骨钙素基因的mRNA表达变化。使用实时逆转录-聚合酶链反应定量检测核因子κB受体激活剂配体(RANKL)和骨保护素(OPG)的mRNA表达。评估与纤维性错构瘤细胞共培养的RAW(264.7)细胞的破骨细胞分化情况。
所有检测的纤维性错构瘤和胫骨骨膜细胞均为CD44+/CD105+/CD45-/CD14-,并表达BMP-2、BMP-4及其受体的mRNA。纤维性错构瘤细胞中COL1A1、碱性磷酸酶和骨钙素基因的基线mRNA表达各不相同。这些基因表达在胫骨骨膜细胞中经BMP处理后上调,但在纤维性错构瘤细胞中未改变或下调。与胫骨骨膜细胞相比,纤维性错构瘤细胞表达更高水平的RANKL和更低水平的OPG。与纤维性错构瘤细胞共培养可增强RAW(264.7)细胞的破骨细胞分化。
纤维性错构瘤细胞维持一些间充质谱系细胞表型,但对BMP不发生成骨细胞分化。它们比胫骨骨膜细胞更易诱导破骨细胞生成。